New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
07:25 EDTBMRNBioMarin coverage transitioned with a Buy at UBS
Target $74.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
06:38 EDTBMRNBioMarin 8.5M share Spot Secondary priced at $93.25
The deal size was increased to 8.5M shares from 7.25M shares. BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering.
January 21, 2015
18:27 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
16:03 EDTBMRNBioMarin files to sell 7.25M shares of common stock
Subscribe for More Information
January 15, 2015
15:26 EDTBMRNSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
January 14, 2015
07:19 EDTBMRNBioMarin volatility at upper end of two-year range as shares at record high
Subscribe for More Information
January 13, 2015
08:53 EDTBMRNProsensa announces holder approval of certain matters relating to BioMarin
Subscribe for More Information
January 12, 2015
13:47 EDTBMRNBioMarin says BMN 190 appeared to show stabilization of disease in study
Subscribe for More Information
13:34 EDTBMRNBioMarin raises 2014 Vimizim sales outlook to $75M-$77M
Subscribe for More Information
07:57 EDTBMRNBioMarin reiterated as a top mid-cap pick at UBS
UBS reiterated BioMarin as a top mid-cap pick for 2015 following meetings with management. The firm cited the breadth of its pipeline and robust catalysts over the next 12-18 months and the closing of its Prosensa acquisition, which will accelerate revenue growth and profitability over the long-term. UBS reiterated its Buy rating and $112 price target on BioMarin shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use